Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis

OBJECTIVE: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: A descriptive retrospective observational study including all patients with RRMS treated with nata...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Rodríguez de Castro, Belén, Barbosa, Cristina Martinez-Múgica, Ayastuy Ruiz, Aitor, Fernández González, Beatriz
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2021
Konular:
Short Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7907687/
https://ncbi.nlm.nih.gov/pubmed/33608441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2019-002048
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller